Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer

 Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer

Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer

Shots:

  • The companies will jointly develop vaccine candidates using Leidos’ PD-1 checkpoint inhibitors combined with GeoVax’s MVA-VLP vaccine platform
  • GeoVax will design, construct, and characterize the developed product and further analysis will be done by Leidos
  • GeoVax’s Modified Vaccinia Ankara (MVA) platform is used for developing in-vivo vaccines in the form of multimeric proteins or non-infectious VLPs (Virus-Like Particle)

Click here to read full press release/ article | Ref: GeoVax | Image: Axios

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post